Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition

Cancer Letters

Volumn 334, Issue 2, 2013, Pages 293-301

  Koshkaryev, Alexander ^a   Piroyan, Aleksandr ^a   Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Bleomycin; Fusogenic lipids; Liposomes; Mice tumor model; Octaarginine

Indexed keywords

ARGININE DERIVATIVE; BLEOMYCIN; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DNA; LIPOSOME; OCTAARGININE; PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL INTERACTION; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; ENCAPSULATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PINOCYTOSIS; PRIORITY JOURNAL; TUMOR VOLUME; ZETA POTENTIAL;

ANIMALS; APOPTOSIS; BLEOMYCIN; CELL GROWTH PROCESSES; DISEASE MODELS, ANIMAL; FEMALE; HELA CELLS; HUMANS; LIPOSOMES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; OLIGOPEPTIDES; PHOSPHATIDYLETHANOLAMINES; RANDOM ALLOCATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84878230631     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.06.008     Document Type: Article

References (31)

1. Torchilin V.P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 2006, 8:343-375.
2. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
3. Chen J., Stubbe J. Bleomycins: towards better therapeutics. Nat. Rev. Cancer 2005, 5:102-112.
4. Iqbal Z.M., Kohn K.W., Ewig R.A., Fornace A.J. Single-strand scission and repair of DNA in mammalian cells by bleomycin. Cancer Res. 1976, 36:3834-3838.
5. Kuo M.T. Preferential damage of active chromatin by bleomycin. Cancer Res. 1981, 41:2439-2443.
6. Giloni L., Takeshita M., Johnson F., Iden C., Grollman A.P. Bleomycin-induced strand-scission of DNA. Mechanism of deoxyribose cleavage. J. Biol. Chem. 1981, 256:8608-8615.
7. Roy S.N., Horwitz S.B. Characterization of the association of radiolabeled bleomycin A2 with HeLa cells. Cancer Res. 1984, 44:1541-1546.
8. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001, 120:617-624.
9. Arndt D., Zeisig R., Bechtel D., Fichtner I. Liposomal bleomycin: increased therapeutic activity and decreased pulmonary toxicity in mice. Drug Deliv. 2001, 8:1-7.
10. Gabizon A., Price D.C., Huberty J., Bresalier R.S., Papahadjopoulos D. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res. 1990, 50:6371-6378.
11. Maekawa S., Sugimachi K., Kitamura M. Selective treatment of metastatic lymph nodes with combination of local hyperthermia and temperature-sensitive liposomes containing bleomycin. Cancer Treat. Rep. 1987, 71:1053-1059.
12. Sur P., Hazra B., Roy D.K., Sur B. Enhancement of the activity of bleomycin on Ehrlich ascites carcinoma cells by liposomal encapsulation. Indian J. Exp. Biol. 1984, 22:115-119.
13. Straubinger R.M., Duzgunes N., Papahadjopoulos D. PH-sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS Lett. 1985, 179:148-154.
14. Torchilin V.P., Zhou F., Huang L. PH-Sensitive liposomes. J. Liposome Res. 1993, 1993(3):201-255.
15. Chu C.J., Dijkstra J., Lai M.Z., Hong K., Szoka F.C. Efficiency of cytoplasmic delivery by pH-sensitive liposomes to cells in culture. Pharm. Res. 1990, 7:824-834.
16. Slepushkin V.A., Simoes S., Dazin P., Newman M.S., Guo L.S., Pedroso de Lima M.C., Duzgunes N. Sterically stabilized pH-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo. J. Biol. Chem. 1997, 272:2382-2388.
17. Sawant R., Torchilin V. Intracellular delivery of nanoparticles with CPPs. Methods Mol. Biol. 2011, 683:431-451.
18. Torchilin V.P. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 2008, 90:604-610.
19. Khalil I.A., Kogure K., Futaki S., Hama S., Akita H., Ueno M., Kishida H., Kudoh M., Mishina Y., Kataoka K., Yamada M., Harashima H. Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery. Gene Ther. 2007, 14:682-689.
20. Zhang C., Tang N., Liu X., Liang W., Xu W., Torchilin V.P. SiRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J. Control Release 2006, 112:229-239.
21. Furukawa R., Yamada Y., Takenaga M., Igarashi R., Harashima H. Octaarginine-modified liposomes enhance the anti-oxidant effect of Lecithinized superoxide dismutase by increasing its cellular uptake. Biochem. Biophys. Res. Commun. 2011, 404:796-801.
22. Fiedler H.P., Wachter J. High-performance liquid chromatographic determination of bleomycins. J. Chromatogr. 1991, 536:343-347.
23. Steinman R.M., Mellman I.S., Muller W.A., Cohn Z.A. Endocytosis and the recycling of plasma membrane. J. Cell Biol. 1983, 96:1-27.
24. Khalil I.A., Kogure K., Futaki S., Harashima H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J. Biol. Chem. 2006, 281:3544-3551.
25. Tyagi M., Rusnati M., Presta M., Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 2001, 276:3254-3261.
26. Khalil I.A., Kogure K., Futaki S., Harashima H. Octaarginine-modified liposomes: enhanced cellular uptake and controlled intracellular trafficking. Int. J. Pharm. 2008, 354:39-48.
27. Brunner J., Barton J.K. Targeting DNA mismatches with rhodium intercalators functionalized with a cell-penetrating peptide. Biochemistry 2006, 45:12295-12302.
28. Gothelf A., Mir L.M., Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat. Rev. 2003, 29:371-387.
29. Torrero M.N., Henk W.G., Li S. Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemogenetherapy. Clin. Cancer Res. 2006, 12:257-263.
30. Campana L.G., Mocellin S., Basso M., Puccetti O., De Salvo G.L., Chiarion-Sileni V., Vecchiato A., Corti L., Rossi C.R., Nitti D. Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. Ann. Surg. Oncol. 2009, 16:191-199.
31. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 2011, 63:131-135.